NCT00193466已完成2 期
Phase II Trial of Rituximab/Fludarabine Followed by CAMPATH-1H in the First-Line Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
- 主要终点
- Complete response rate
研究概览
简要总结
In this multicenter trial, we will investigate the use of fludarabine plus rituximab, followed by Campath-1H, in previously untreated patients with CLL/SLL. Patients who are elderly, or who are considered unlikely to tolerate this combination therapy well, will receive single agent rituximab followed by Campath-1H.
详细描述
Upon determination of eligibility, all patients will receive:
Fludarabine + Rituximab + CAMPATH-1H
Patients who are judged by the investigator not to be candidates for fludarabine due to advanced age, marginal performance status or coexistent medical conditions will receive rituximab alone followed by CAMPATH-1H.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •To be included in this study, you must meet the following criteria:
- •Histologically proven B-cell CLL/SLL
- •Positive staining for CD20 antigen
- •No systemic chemotherapy.
- •Measurable or evaluable disease
- •Able to perform activities of daily living with minimal assistance
- •Age > 18 years
- •Life expectancy > 12 weeks
- •Adequate liver and kidney function
- •Must be accessible for treatment and follow-up
- •Must give written informed consent prior to entering this study.
排除标准
- •You cannot participate in this study if any of the following apply to you:
- •Female pregnant or lactating
- •Unstabilized active infection on the basis of neutropenia
- •History of previous severe opportunistic infections
- •Serious underlying medical conditions
- •Central nervous system involvement
- •History of other neoplasms, either active or treated within five years
- •Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
结局指标
主要结局
Complete response rate
次要结局
- Molecular complete response rate
- Progression free survival
- Overall toxicity
研究者
相似试验
已完成
2 期
Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic LeukemiaB-cell Chronic Lymphocytic LeukemiaStage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic LeukemiaStage IV Chronic Lymphocytic LeukemiaNCT00098670National Cancer Institute (NCI)102
已完成
2 期
Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's LymphomaLymphoma, Non-HodgkinMALT LymphomaNCT00117156Dana-Farber Cancer Institute26
终止
2 期
Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.Acute Myeloid Leukemia, AdultAML, AdultAMLNCT04425655University of California, San Diego2
已完成
1 期
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukemiaNCT00536341SCRI Development Innovations, LLC64
终止
2 期
Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell LymphomaMantle Cell LymphomaNCT00183989University of Southern California30